TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed HCC (or fulfilling AASLD criteria for HCC diagnosis in HBsAg positive subjects with cirrhosis in case biopsy is not feasible)~2. Disease must not be amenable to potentially curative surgery~3. Without prior systemic nor transarterial treatment~4. Prior surgery or local therapy is allowed but the target lesion must have not been previously treated~5. Child-Pugh stage A liver function~6. ECOG performance 0-2~7. Life expectancy longer than 12 weeks~8. At least one measurable treatment lesion according to modified RECIST criteria~9. Adequate haematological, hepatic and renal function~Exclusion Criteria:~1. Contra-indications to TACE treatment:~   * Main portal vein thrombosis or occlusion~  * Evidence of biliary obstruction~  * Presence of extra-hepatic disease~2. Diffuse-type HCC~3. Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment.~4. Any form of prior transarterial therapy or systemic therapy for HCC.~5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors or CYP3A4 or CYP1A2 inducers.~6. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.~7. Any haemorrhage or bleeding event of CTCAE Grade 3 or more within 4 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE+Axitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (main):~* Untreated SCCHN of oral cavity (anterior tongue, floor of mouth, cheek)/soft palate, categories T1N1-2M0,T2N1-2M0,T3N0-2M0,T4N0-2M0 (T4 allowed only if invasion of mandible is negligible i. e. 5mm or less) scheduled for SOC~* Primary tumor and any positive node(s) measurable in 2 dimensions~* Normal immune function~* No immunosuppressives with 1 year of entry~* KPS\>70/100~* Age\>18~* Male or Female (non-pregnant)~* Life expectancy \>6 months~* Able to take oral medication~* Able to provide informed consent~Exclusion Criteria (main):~* Subjects to be treated with other than SOC~* Tumor invasion of bone (also see inclusion criteria)~* Tumor classifications T1N0, T2N0, T4N3, any TN classification with M1~* Tumors in locations other than those specified in inclusion criteria~* Active peptic ulcer (or on full-dose therapeutic anti-coagulants)~* Prior resection of jugular nodes ipsilateral to tumor~* Acute or chronic viral, bacterial immune or other disease associated with abnormal immune function~* Subjects on hemodialysis or peritoneal dialysis; or having a history of~* History of asthma, allergy to fluoroquinolone antibiotics, congestive heart failure, or on hemodialysis or peritoneal dialysis~* Any condition that in the opinion of the investigator would cause the subject to be unable to participate or tolerate the protocol regimen~* Failure to meet inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LI + CIZ + SOC (Type: EXPERIMENTAL): LI plus CIZ (cyclophosphamide, indomethacin and zinc-multivitamins) was given as neoadjuvant therapy prior to standard of care (SOC).
- Standard of Care (SOC) only (Type: ACTIVE_COMPARATOR): SOC for previously untreated SCCHN patients is currently surgery (with curative intent) followed by either radiotherapy or combined radiochemotherapy depending on the patient's risk status for recurrence as determined at surgery.
- LI + SOC (Type: EXPERIMENTAL): LI was administered without CIZ to determine the contribution of CIZ to the effects of LI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any non-cephalic presentation~* singleton pregnancy~* \>/= 37 weeks gestational age~* normal amniotic fluid volume~* reassuring fetal heart rate~Exclusion Criteria:~* labor~* ruptured membranes~* history of third trimester bleeding~* any pre-existing uterine scar~* pregnancy induced hypertension and gestational diabetes~* oligohydramnios and polyhydramnios~* intrauterine growth restriction or macrosomia~* hypotension or any serious medical illness~* inability to comprehend the consent form

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
- 2 (Type: PLACEBO_COMPARATOR): Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type Ⅱ diabetes mellitus~* Between 18 years and 80 years old~* The patient who has been taking oral hypoglycemic agent since 3 months with HbA1c 6.5 to 9% at screening test or who is drug naive or stopped taking oral hypoglycemic agent more then 3 months with HbA1c 7 to 10% at screening test~* BMI between 21kg/㎡ and 40kg/㎡~* Diagnosis of type Ⅱ diabetes before 3 months~* C-peptide level is over 1.0 ng/ml~* Condition for female having contraception methods, surgical sterilization or menopause~* Condition for male agreeing to use of recommendatory and appropriate contraception method~* Agreement with written informed consent~Exclusion Criteria:~* Type I diabetes, gestational diabetes or secondary diabetes~* Treatment with insulin or thiazolidinediones within 60 days~* Fasting Plasma Glucose level is over 250 mg/dl~* Triglyceride level is 500 mg/dl and over~* Uncontrollable hypertension(Although treat with antihypertension agent, systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater than 90 mmHg)~* History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months~* Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 2.5 times as high as upper normal limit(UNL)~* Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit~* Anemia for any reason~* Needs treatment for acute disease, uncontrolled other diseae or diabetic complications~* Abnormality of thyroid function(out of normal TSH range )~* History of proliferative diabetic retinopathy~* In treatment concomitant drug having severe risk drug interaction with investigational drug~* History of cancer within 5 years~* History of drug abuse or alcoholism~* Hepatitis B Antigen(HBsAg) test is positive~* Treatment systemic or inhalant corticosteroids within 1 month prior to Screening~* Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones~* Fertile women who not practice contraception with appropriate methods~* Pregnant women or nursing mothers~* Has a contraindication to treatment investigational drug from the medical and psychogenic side~* An impossible one who participates in clinical trial by legal or investigator's decision~* Participated in other trial within 4 weeks~* Participating in other trial at present

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CKD-501 0.5mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with CKD and in dialysis with preformed anti-HLA antibodies (non-DSA, DSA or both), negative T-CDC CXM and at least one antibody MFI \> 3000~Exclusion Criteria:~* Prior malignancy within 2 years excluding adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ and prostate cancer Gleason \<6 and prostate-specific antigen (PSA) \<10 ng/mL.~* Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV~* Clinical signs of ongoing infectious disease.~* Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure \> New York Heart Association (NYHA) grade 3, unstable coronary disease or oxygen dependent chronic obstructive pulmonary disease (COPD)~* History of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study~* Hypogammaglobulinemia defined as any values of P-total IgG less than 3 g/L~* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to IdeS (e. g streptokinase and/or staphylokinase)~* Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 4 months of the first administration of investigational product in this study.~* Patients consented and screened but not dosed in previous studies are not excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): IdeS as a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of bariatric or upper-gastrointestinal surgery (RYGB, VSG, gastrectomy, esophagectomy, or Nissen fundoplication) at least 12 months prior to the start of Screening~* History of recurrent hypoglycemia occurring after bariatric or upper-GI surgery, as documented in the medical record.~* Body mass index (BMI) of up to 40 kg/m2~* If female, must not be breastfeeding and must have a negative urine pregnancy test result~Exclusion Criteria:~* Major surgery within 6 months before randomization.~* History of or current hyperinsulinism other than Acquired Hyperinsulinism (e.g., insulin autoimmune hypoglycemia).~* Use of agents that may interfere with glucose metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avexitide 45 mg twice daily then avexitide 90 mg once daily (Type: EXPERIMENTAL): Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
- Avexitide 45 mg once daily then avexitide 90 mg twice daily (Type: EXPERIMENTAL): Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults above 50 years of age~Exclusion Criteria:~* Participants who received BCG in the last 10 years will be excluded.~* Adults who were mild to severe ill in the last 2 week will be excluded.~* Adults how have been in contact with the health system (hospital or health center) for the last 14 days will be excluded.~* People that show signs of overt disease will not be enrolled, but treated according to local standards and invited back when better.~* If the person has any sign of TB, they will excluded and be referred to the TB clinic for further investigations and treatment.~* All participants will be tested for HIV. If the test is positive, they will have an opportunity to talk with a psychologist, and we will refer them to the HIV clinic. HIV positive persons will be excluded from the present study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Intervention arm, these participants will receive BCG vaccination.
- Placebo arm (Type: PLACEBO_COMPARATOR): The placebo arm will receive BCG solvent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Data collection will be compiled from all the participants admitted to the Medical Intensive Care Unit (MICU).~* For skin cultures: One randomly selected (intubated or non-intubated) patient in each intervention group~Exclusion Criteria:~* Patients with greater than 20% of body surface area disruption in skin integrity will be excluded from participation in the 2% CHG Antiseptic Cloths arm of the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chlorhexidine gluconate (CHG) (Type: EXPERIMENTAL): daily skin cleansing with no-rinse, 2% CHG-impregnated cloths (Sage)
- Soap & Water (Type: ACTIVE_COMPARATOR): bathing daily with bar soap (Dial Corp., Scottsdale, AZ) warm water, and cotton washcloths

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have type 2 diabetes mellitus on diet/exercise therapy~Exclusion Criteria:~* Patients have type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 50 mg QD (Type: EXPERIMENTAL): sitagliptin 50 mg orally once daily (QD=once daily)
- Voglibose 0.2 mg TID (Type: ACTIVE_COMPARATOR): voglibose 0.2 mg orally three times daily (TID= three times daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Females ≥18 and \<65 years~* Clinical diagnosis of symptomatic acute VVC~* Positive KOH .At least one vulvovaginal sign (vulvovaginal erythema, edema, or excoriation).~* At least one vulvovaginal symptom (vulvovaginal itching, burning, or irritation)~* A minimum composite vulvovaginal signs and symptoms score of ≥6~* must be be able to swallow capsules~Exclusion Criteria:~* Evidence of major organ system disease~* History of cervical cancer~* History of diabetes mellitus~* Pregnant~* Recent use of systemic antifungal drugs or systemic antimicrobial therapy for any reason~* Recent use of drugs to treat vaginal infections~* Recent use of immunosuppressive therapies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VT-1161 300mg QD (Type: EXPERIMENTAL): None
- VT-1161 600mg QD (Type: EXPERIMENTAL): None
- VT-1161 600mg BID (Type: EXPERIMENTAL): None
- Fluconazole 150mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Type 2 diabetes mellitus (diagnosed clinically) for at least 12 months~* Currently treated with premixed/self-mixed human insulin (proportion of short-acting insulin is equal to or lower than 30%) BID (twice daily) combined with metformin with or without alpha-glucosidase inhibitor for at least 3 months prior to screening visit (Visit 1) with the minimum dose stated: Metformin: at least 1500 mg/day or maximum tolerated dose at least 1000 mg/day (with unchanged dosing within 3 months prior to Visit 1) OR alpha-glucosidase inhibitors: acarbose or miglitol at least 150 mg/day, or voglibose at least 0.6 mg/day~* Total daily insulin dose below 1.4 IU/Kg~* HbA1c above or equal to 7.0% and below or equal to 9.5% (central laboratory)~* Body Mass Index (BMI) below or equal to 35.0 kg/m\^2~Exclusion Criteria:~* Treatment with any insulin secretagogue, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 (GLP-1) receptor agonists within the last 3 months prior to Visit 1~* Previous use of insulin intensification treatment (premixed insulin thrice daily, basal bolus regimen, and continuous subcutaneous insulin infusion (CSII)) for more than 14 days~* Previous use of any insulin other than premixed/self-mixed human insulin (proportion of short acting insulin equal to or lower than 30%) BID within 3 month prior to Visit 1~* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode, during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Known proliferative retinopathy or maculopathy requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Subject-driven titration (Type: EXPERIMENTAL): None
- Investigator-driven titration (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of congenital C1-INH deficiency (HAE type I or II) and assessed by the investigator to likely require intravenous (IV) Berinert treatment during the study period.~* Male or female, ≥ 12 years of age at the time of signing informed consent.~* Written informed consent for study participation obtained before undergoing any study specific procedures.~Exclusion Criteria:~* Incurable malignancies in the last 6 months prior to study entry.~* Acquired angioedema due to C1-INH deficiency.~* All other types of angioedema not associated with C1-INH deficiency.~* Use of any C1-INH products other than Berinert within 30 days before the study, or planned use during the study.~* Immunization within 30 days prior to study entry.~* Autoimmune conditions requiring use of immunosuppressants during the study.~* Known or suspected hypersensitivity to C1-INH.~* Participation in any of the previous Berinert studies from which anti-C1-INH antibody results were submitted to the Food and Drug Administration.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Berinert (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete